This mobile application (app) was developed to facilitate monitoring and evaluation of programmatic management of LTBI. Through the app, health-care workers can collect client information used to monitor indicators for the management of LTBI. The app can be modified to meet the specific needs of the country using the app.
An infographic that emphasizes the severity of TB and HIV coinfection. The infographic includes information on how many people died in 2017 from AIDS-related TB, how many lives have been saved since 2000 due to TB treatment, and more.
The video describes ways to effectively manage active TB by providing information on TB testing, diagnosis, and treatment.
This fact sheet contains information on TB testing and treatment for pregnant or breastfeeding mothers. The resource also contains information on the differences between TB disease and latent TB infection.
This fact sheet identifies persons who should be tested for tuberculosis (TB) and lists conditions that increase a person's risk for progression to active TB, such as the human immunodeficiency virus (HIV).
This fact sheet is intended as a convenient but not comprehensive reference for managing the care of HIV-infected patients with drug susceptible TB.
This report presents information about the Global TB Drug Facility, a program designed to ensure access to and the availability of TB drugs.
This CD-ROM contains electronic copies of materials such as educational products, TB guidelines, Morbidity & Mortality Weekly Reports (MMWR), surveillance reports, and slide sets, many of which are currently located on the CDC Division of TB Elimination Internet site.
This pocket-size drug treatment card for clinicians provides information on the standard anti-tuberculosis therapy for active disease in children, including dosages, daily and intermittent regimens, side effects, treatment information and visual depictions of first-line medications.
This booklet answers questions about the 4-drug fixed-dose combinations containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol that were added to the WHO Model List of Essential Drugs for the treatment of TB.
